Aeterna Zentaris Announces Notice of Allowance for U.S. Patent Covering AEZS-150 for the Potential Treatment of Chronic Hypoparathyroidism
02 mars 2022 08h05 HE
|
Aeterna Zentaris Inc
– Notice of allowance received by Company’s licensor, The University of Sheffield (UK) bolsters intellectual property of AEZS-150 in development for the potential treatment of chronic...
Aeterna Zentaris to Present at the 2022 BIO CEO & Investor Conference
07 févr. 2022 08h05 HE
|
Aeterna Zentaris Inc
CHARLESTON, S.C., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and...
Aeterna Zentaris Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
26 janv. 2022 16h05 HE
|
Aeterna Zentaris Inc
CHARLESTON, S.C., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and...
Aeterna Zentaris to Present at the H.C. Wainwright BioConnect Conference
05 janv. 2022 08h36 HE
|
Aeterna Zentaris Inc
CHARLESTON, S.C., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and...
Aeterna Zentaris Regains Compliance with Nasdaq Minimum Bid Price Requirement
22 mars 2021 16h05 HE
|
Aeterna Zentaris Inc
CHARLESTON, S.C., March 22, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and...
Aeterna Zentaris Announces Exclusive License Agreement and Research Contract with Julius-Maximilians-University Wuerzburg for Development of a Potential Oral Prophylactic Bacterial Vaccine Against COVID-19
15 mars 2021 08h05 HE
|
Aeterna Zentaris Inc
- Company secures next step to continue to build-out pipeline of assets - Company exercised its option to enter into an exclusive license of intellectual property for the development of a...
Aeterna Zentaris Amends License Agreement with Novo Nordisk for Commercialization and Development of Macimorelin
16 nov. 2020 08h05 HE
|
Aeterna Zentaris Inc
- Company to receive upfront payment of €5 million replacing a later stage regulatory approval milestone of U.S.$5 million - Novo Nordisk committing to fund €9 million of the budgeted AEZS-130-P02...
Aeterna Zentaris Reports Third Quarter 2020 Financial Results and Provides Business Update
06 nov. 2020 08h35 HE
|
Aeterna Zentaris Inc
– Pivotal Phase 3 safety and efficacy study AEZS-130-P02 (“Study P02”) expected to commence in Q1 2021 – Continue to advance discussions to secure a commercialization partner for macimorelin in...
Aeterna Zentaris Reports Second Quarter 2020 Financial Results and Provides Business Update
06 août 2020 08h35 HE
|
Aeterna Zentaris Inc
– Positive results from AEZS-130-P01 (“Study P01”) confirmed dosing regimen of macimorelin as a potential diagnostic for childhood-onset growth hormone deficiency – Safety and efficacy...
Aeterna Zentaris Announces Continued Expansion of Intellectual Property Portfolio for Macimorelin with Additional Patent Applications
31 juil. 2020 07h35 HE
|
Aeterna Zentaris Inc
CHARLESTON, S.C., July 31, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and...